Debra Kelsh

421 total citations
16 papers, 204 citations indexed

About

Debra Kelsh is a scholar working on Public Health, Environmental and Occupational Health, Pharmacology and Physiology. According to data from OpenAlex, Debra Kelsh has authored 16 papers receiving a total of 204 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Public Health, Environmental and Occupational Health, 7 papers in Pharmacology and 4 papers in Physiology. Recurrent topics in Debra Kelsh's work include Opioid Use Disorder Treatment (8 papers), Treatment of Major Depression (5 papers) and Attention Deficit Hyperactivity Disorder (3 papers). Debra Kelsh is often cited by papers focused on Opioid Use Disorder Treatment (8 papers), Treatment of Major Depression (5 papers) and Attention Deficit Hyperactivity Disorder (3 papers). Debra Kelsh collaborates with scholars based in United States, Canada and Norway. Debra Kelsh's co-authors include Bradley Vince, Jasper Dingemanse, Mike Ufer, Kerri A. Schoedel, Sandra D. Comer, Naama Levy‐Cooperman, Michelle R. Lofwall, Sharon Walsh, Jermaine D. Jones and Marion A. Coe and has published in prestigious journals such as Journal of the American Academy of Child & Adolescent Psychiatry, SLEEP and JAMA Psychiatry.

In The Last Decade

Debra Kelsh

16 papers receiving 193 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Debra Kelsh United States 9 71 51 50 43 40 16 204
Brent Boyett United States 9 48 0.7× 33 0.6× 25 0.5× 89 2.1× 72 1.8× 16 206
T. Rico United States 5 33 0.5× 112 2.2× 78 1.6× 15 0.3× 86 2.1× 8 240
Joseph D. Deak United States 10 27 0.4× 21 0.4× 25 0.5× 48 1.1× 53 1.3× 26 290
A. Benjamin Srivastava United States 7 49 0.7× 53 1.0× 14 0.3× 52 1.2× 29 0.7× 12 202
Shirley Linzy Israel 8 115 1.6× 24 0.5× 14 0.3× 171 4.0× 78 1.9× 10 412
Markus Kölle Germany 9 42 0.6× 81 1.6× 13 0.3× 29 0.7× 38 0.9× 24 248
Pertti Heikman Finland 10 114 1.6× 32 0.6× 11 0.2× 52 1.2× 116 2.9× 16 348
Sergio Mameli Italy 7 40 0.6× 18 0.4× 11 0.2× 27 0.6× 33 0.8× 8 205
Britahny M. Baskin United States 6 54 0.8× 38 0.7× 19 0.4× 84 2.0× 41 1.0× 12 260
H. Rowland Pearsall United States 12 67 0.9× 13 0.3× 27 0.5× 111 2.6× 47 1.2× 20 323

Countries citing papers authored by Debra Kelsh

Since Specialization
Citations

This map shows the geographic impact of Debra Kelsh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Debra Kelsh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Debra Kelsh more than expected).

Fields of papers citing papers by Debra Kelsh

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Debra Kelsh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Debra Kelsh. The network helps show where Debra Kelsh may publish in the future.

Co-authorship network of co-authors of Debra Kelsh

This figure shows the co-authorship network connecting the top 25 collaborators of Debra Kelsh. A scholar is included among the top collaborators of Debra Kelsh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Debra Kelsh. Debra Kelsh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
2.
Walzer, Mark, et al.. (2023). A phase 1b study to investigate the potential interactions between ASP8062 and buprenorphine/naloxone in patients with opioid use disorder. Journal of Psychopharmacology. 37(2). 144–154. 2 indexed citations
3.
Shram, Megan J., Beatrice Setnik, Lynn R. Webster, et al.. (2022). Oral, intranasal, and intravenous abuse potential of serdexmethylphenidate, a novel prodrug of d-methylphenidate. Current Medical Research and Opinion. 38(7). 1237–1250. 7 indexed citations
4.
Sun, Dajun, Zhichuan Li, Karthika Natarajan, et al.. (2021). Particle size affects pharmacokinetics of milled oxycodone hydrochloride tablet products following nasal insufflation in nondependent, recreational opioid users. Clinical and Translational Science. 14(5). 1977–1987. 2 indexed citations
5.
Ufer, Mike, Debra Kelsh, Kerri A. Schoedel, & Jasper Dingemanse. (2021). Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem. SLEEP. 45(3). 32 indexed citations
6.
Tarabar, Sanela, Debra Kelsh, Bradley Vince, et al.. (2020). Phase I Pharmacokinetic Study of Fixed-Dose Combinations of Ibuprofen and Acetaminophen in Healthy Adult and Adolescent Populations. Drugs in R&D. 20(1). 23–37. 10 indexed citations
7.
Mendell, Jeanne, Naama Levy‐Cooperman, Bradley Vince, et al.. (2019). Abuse potential of mirogabalin in recreational polydrug users. Therapeutic Advances in Drug Safety. 10. 584377984–584377984. 13 indexed citations
8.
Jones, Jermaine D., Shanna Babalonis, Ronald N. Marcus, et al.. (2019). A randomized, double‐blind, placebo‐controlled study of the kappa opioid receptor antagonist, CERC‐501, in a human laboratory model of smoking behavior. Addiction Biology. 25(4). e12799–e12799. 23 indexed citations
9.
10.
Henningfield, Jack E., Suresh Siddhanti, Lin Lü, et al.. (2019). Human Abuse Potential of Oral NKTR-181 in Recreational Opioid Users: A Randomized, Double-Blind, Crossover Study. Pain Medicine. 21(2). e114–e126. 8 indexed citations
11.
Pathak, Sanjeev, Bradley Vince, Debra Kelsh, et al.. (2018). Abuse Potential of Buprenorphine/Samidorphan Combination Compared to Buprenorphine and Placebo: A Phase 1 Randomized Controlled Trial. The Journal of Clinical Pharmacology. 59(2). 206–217. 8 indexed citations
12.
Pathak, Sanjeev, Bradley Vince, Debra Kelsh, et al.. (2018). Abuse Potential of Samidorphan: A Phase I, Oxycodone‐, Pentazocine‐, Naltrexone‐, and Placebo‐Controlled Study. The Journal of Clinical Pharmacology. 59(2). 218–228. 11 indexed citations
13.
Braeckman, Rene A., et al.. (2018). 2.54 Human Abuse Potential of Intravenous Serdexmethylphenidate (SDX), A Novel Prodrug of D-Methylphenidate, in Recreational Stimulant Abusers. Journal of the American Academy of Child & Adolescent Psychiatry. 57(10). S176–S176. 1 indexed citations
14.
Carter, Lawrence P., Jack E. Henningfield, Yuan Lü, et al.. (2018). A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor. Journal of Psychopharmacology. 32(12). 1351–1361. 21 indexed citations
15.
Walsh, Sharon, Sandra D. Comer, Michelle R. Lofwall, et al.. (2017). Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder. JAMA Psychiatry. 74(9). 894–894. 60 indexed citations
16.
Shusterman, Neil H., et al.. (2016). (443) Evaluation of the clinical abuse potential of Opana ER versus oxymorphone HCl powder. Journal of Pain. 17(4). S85–S85. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Brent Boyett Breakdown of academic impact, for papers by T. Rico Breakdown of academic impact, for papers by Joseph D. Deak Breakdown of academic impact, for papers by A. Benjamin Srivastava Breakdown of academic impact, for papers by Shirley Linzy Breakdown of academic impact, for papers by Markus Kölle Breakdown of academic impact, for papers by Pertti Heikman Breakdown of academic impact, for papers by Sergio Mameli Breakdown of academic impact, for papers by Britahny M. Baskin Breakdown of academic impact, for papers by H. Rowland Pearsall
Rankless by CCL
2026